Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has issued an update.
JCR Pharmaceuticals and Modalis Therapeutics have announced a progression to the next phase of their joint research agreement, following the successful validation of an initial proof of concept for a novel gene therapy targeting a central nervous system disease. This collaboration leverages JCR’s J-Brain Cargo® technology and Modalis’ CRISPR-GNDM® platform, aiming to enhance the efficacy and safety of gene therapy treatments. The partnership marks a strategic advancement for both companies, although the financial impact on this fiscal year is expected to be minor.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on advancing treatments for rare and genetic diseases, with nearly five decades of expertise in Japan and expansion efforts into the US, Europe, and Latin America. Their innovative therapies target conditions like growth disorders, Fabry disease, acute graft-versus-host disease, and renal anemia. Modalis Therapeutics Corporation, founded in 2016, is a forerunner in epigenetic medicine, developing therapeutics for serious genetic disorders, including neuromuscular and CNS diseases, using their proprietary CRISPR-GNDM® technology.
YTD Price Performance: 0%
Average Trading Volume: 365,374
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen75.12B
See more data about 4552 stock on TipRanks’ Stock Analysis page.